Tao Meng

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Metastatic Colorectal Cancer

Diffusion Weighted Imaging

Top Venues

Molecular cancer therapeutics

Cancer research

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Weining Weng, Tao Meng, Qianqian Zhao, Yi Shen, Guoxiang Fu, Jing Shi, Yue Zhang, Zhaohui Wang, Mingqiao Wang, Rong Pan, Linjie Ma, Caiwei Chen, Lijun Wang, Biao Zhou, Hui Zhang, Junyi Pu, Jianjian Zhang, Yi Peter Hu, Guoqiang Hua, Yu Qian, Shu-Hui Liu, Wen-Hao Hu, Xun Meng
Antibody-exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer. Cancer discovery (2023)
Weining Weng, Tao Meng, Junyi Pu, Linjie Ma, Yi Shen, Zhaohui Wang, Rong Pan, Mingqiao Wang, Caiwei Chen, Lijun Wang, Jianjian Zhang, Biao Zhou, Siyuan Shao, Yu Qian, Shu-Hui Liu, Wen-Hao Hu, Xun Meng
AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors. Molecular cancer therapeutics (2023)
Jing Shi, Tao Jiao, Qian Guo, Weining Weng, Linjie Ma, Qing Zhang, Lijun Wang, Jianjian Zhang, Caiwei Chen, Yaling Huang, Mingqiao Wang, Rong Pan, Yanfang Tang, Wen-Hao Hu, Tao Meng, Shu-Hui Liu, Jun Guo, Yan Kong, Xun Meng
A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma. Cancer research (2023)
Chao Kong, Junyi Pu, Qianqian Zhao, Weining Weng, Linjie Ma, Yu Qian, Wen-Hao Hu, Xun Meng, Tao Meng
MTX-13, a novel PTK7-directed antibody-drug conjugate with widened therapeutic index shows sustained tumor regressions for a broader spectrum of PTK7-positive tumors. Molecular cancer therapeutics (2023)